Literature DB >> 19067189

Season of diagnosis and prognosis in breast and prostate cancer.

Lars Holmberg1, Jan Adolfsson, Lorelei Mucci, Hans Garmo, Hans Olov Adami, Henrik Möller, Jan-Erik Johansson, Meir Stampfer.   

Abstract

BACKGROUND: Patients with breast or prostate cancer diagnosed during the summer season have been observed to have better survival. The extent to which this is due to biological and/or health care system related factors is unclear.
METHODS: Using the Swedish Cancer Register and clinical databases, we analyzed overall survival by month of diagnosis among the incident cases of breast (n = 89,630) cancer and prostate (n = 72,375) cancer diagnosed from 1960 to 2004. We retrieved data on tumor stage from 1976 for breast cancer and 1997 for prostate cancer. Cox proportional hazards models were used to calculate relative risk of survival by the season of diagnosis.
RESULTS: There was a higher hazard ratio of death in men and women diagnosed with cancer in the summer with a relative hazard of 1.20 (95% confidence interval 1.15-1.25) for July for prostate cancer and 1.14 (95% confidence interval 1.09-1.19) for August for breast cancer when compared to being diagnosed in January. This difference coincided with a lower mean number of cases diagnosed per day, and a higher proportion of advanced cases diagnosed in the summer. This pattern of presentation was stronger in the later years.
CONCLUSION: The difference in stage distribution explains the seasonal variation in prognosis seen in this study. The variation may be because of structure of the health care system and a strong tradition of vacationing from mid June to mid August. Thus, the health care infrastructure and the late presentation of symptomatic disease may influence cancer survival studied by season of diagnosis substantially.

Entities:  

Mesh:

Year:  2008        PMID: 19067189     DOI: 10.1007/s10552-008-9279-6

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  7 in total

1.  Seasonal variation in expression of markers in the vitamin D pathway in prostate tissue.

Authors:  Mara M Epstein; Ove Andrén; Julie L Kasperzyk; Irene M Shui; Kathryn L Penney; Katja Fall; Jennifer R Rider; Meir J Stampfer; Swen-Olof Andersson; Edward Giovannucci; Lorelei A Mucci
Journal:  Cancer Causes Control       Date:  2012-06-19       Impact factor: 2.506

2.  Seasonal variations of cancer incidence and prognosis.

Authors:  Johan Moan; Zoya Lagunova; Oyvind Bruland; Asta Juzeniene
Journal:  Dermatoendocrinol       Date:  2010-04

3.  Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer.

Authors:  Fang Fang; Julie L Kasperzyk; Irene Shui; Whitney Hendrickson; Bruce W Hollis; Katja Fall; Jing Ma; J Michael Gaziano; Meir J Stampfer; Lorelei A Mucci; Edward Giovannucci
Journal:  PLoS One       Date:  2011-04-06       Impact factor: 3.240

4.  Breast cancer survival and season of surgery: an ecological open cohort study.

Authors:  Dorthe Teilum; Karsten D Bjerre; Anne M Tjønneland; Niels Kroman
Journal:  BMJ Open       Date:  2012-01-05       Impact factor: 2.692

5.  Low serum 25-hydroxyvitamin d concentrations are associated with increased risk for melanoma and unfavourable prognosis.

Authors:  Benjamin Bade; Alexander Zdebik; Stefan Wagenpfeil; Stefan Gräber; Jürgen Geisel; Thomas Vogt; Jörg Reichrath
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

6.  No Impact of Seasonality of Diagnoses on Baseline Tumor Immune Infiltration, Response to Treatment, and Prognosis in BC Patients Treated with NAC.

Authors:  Beatriz Grandal; Ashwaq Aljehani; Elise Dumas; Eric Daoud; Floriane Jochum; Paul Gougis; Judicaël Hotton; Amélie Lemoine; Sophie Michel; Enora Laas; Marick Laé; Jean-Yves Pierga; Khaoula Alaoui Ismaili; Florence Lerebours; Fabien Reyal; Anne Sophie Hamy
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

7.  Simulation model of disease incidence driven by diagnostic activity.

Authors:  Marcus Westerberg; Rolf Larsson; Lars Holmberg; Pär Stattin; Hans Garmo
Journal:  Stat Med       Date:  2020-11-25       Impact factor: 2.373

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.